426 related articles for article (PubMed ID: 21301005)
1. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
3. Evolution of systemic therapy of advanced hepatocellular carcinoma.
Yau T; Chan P; Epstein R; Poon RT
World J Gastroenterol; 2008 Nov; 14(42):6437-41. PubMed ID: 19030192
[TBL] [Abstract][Full Text] [Related]
4. New pharmacological developments in the treatment of hepatocellular cancer.
Gusani NJ; Jiang Y; Kimchi ET; Staveley-O'Carroll KF; Cheng H; Ajani JA
Drugs; 2009; 69(18):2533-40. PubMed ID: 19943706
[TBL] [Abstract][Full Text] [Related]
5. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
6. [Treatment of advanced hepatocellular carcinoma].
Forner A; Rodríguez De Lope C; Reig M; Bruix J
Gastroenterol Hepatol; 2010; 33(6):461-8. PubMed ID: 20227796
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib, a systemic therapy for hepatocellular carcinoma.
Méndez-Sánchez N; Vásquez-Fernández F; Zamora-Valdés D; Uribe M
Ann Hepatol; 2008; 7(1):46-51. PubMed ID: 18376365
[TBL] [Abstract][Full Text] [Related]
8. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
[TBL] [Abstract][Full Text] [Related]
9. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Greten TF; Manns MP; Malek N
Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
[TBL] [Abstract][Full Text] [Related]
10. Signaling pathways in hepatocellular carcinoma.
Sia D; Villanueva A
Oncology; 2011; 81 Suppl 1():18-23. PubMed ID: 22212931
[TBL] [Abstract][Full Text] [Related]
11. [Hepatocellular carcinoma].
Yamashita T; Arai K; Kaneko S
Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
[TBL] [Abstract][Full Text] [Related]
12. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Sakata K; Matsugaki S; Kajiwara M; Fukuizumi K; Tajiri N; Matsukuma N; Sakai T; Ono N; Yano Y; Koga H; Kurogi J; Takata A; Sumie S; Satani M; Yamada S; Niizeki T; Aino H; Iwamoto H; Torimura T; Sata M
Oncology; 2013; 84(2):108-14. PubMed ID: 23147476
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib for liver cancer: the horizon broadens.
Johnson P; Billingham L
Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
[No Abstract] [Full Text] [Related]
15. Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.
Reig M; Bruix J
J Hepatobiliary Pancreat Sci; 2010 Jul; 17(4):420-1. PubMed ID: 19890601
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
17. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
Horger M; Lauer UM; Schraml C; Berg CP; Koppenhöfer U; Claussen CD; Gregor M; Bitzer M
BMC Cancer; 2009 Jun; 9():208. PubMed ID: 19558720
[TBL] [Abstract][Full Text] [Related]
18. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Park MS; Kim EH; Seong J; Lee DY; Han KH
Liver Int; 2012 Aug; 32(7):1120-7. PubMed ID: 22524688
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Yau T; Chan P; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT
Cancer; 2009 Jan; 115(2):428-36. PubMed ID: 19107763
[TBL] [Abstract][Full Text] [Related]
20. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
Huynh H; Ong RW; Li PY; Lee SS; Yang S; Chong LW; Luu DA; Jong CT; Lam IW
Anticancer Agents Med Chem; 2011 Jul; 11(6):560-75. PubMed ID: 21554207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]